Investor Presentation 2025-26
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Syschem India Ltd, a BSE-listed pharmaceutical API manufacturer, delivered exceptional FY 2025-26 results with revenue of ₹655 Cr, up 70% YoY from ₹386 Cr. EBITDA surged 423% to ₹21.11 Cr while PAT jumped 2,276% to ₹10.93 Cr, driven by strong production ramp-up from 463 MT in Q1 to 1,239 MT in Q4. Total annual production reached 3,039 MT versus 1,280 MT prior year (85% increase). The company manufactures APIs including Amoxicillin, Cephalexin, Ampicillin, and Flucloxacillin, serving 200+ customers across 12+ countries. Management is pursuing backward integration and new dedicated plants for penicillin-based products, with WHO-GMP certification underway. EBITDA margin expanded to 3.22% and PAT margin to 1.67%, indicating improving profitability despite the margins still being relatively modest for the industry.
The company shows strong operational execution with dramatic profit growth outpacing revenue growth, signalling improving operating leverage. However, low absolute margins and heavy Capex spending with deferred tax impact on Q4 PAT warrant close monitoring. The 70% revenue growth demonstrates significant market traction but sustainability of this growth rate needs validation.